Research platform on molecular testing, treatment, and disease progression in patients with non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC)

Lung cancer develops when cells in the lungs multiply uncontrollably and form tumors. There are two main types: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLC is the more common form and usually grows more slowly, while SCLC is more aggressive and can spread more quickly throughout the body. Treatment depends on the type of tumor and may include surgery, radiation therapy, or drug therapy, among other options. A histological examination of the tumor is particularly important for identifying specific characteristics (biomarkers) and thus selecting targeted, effective therapies. This is especially important for patients whose cancer is already advanced or has spread to other parts of the body (metastasized). Specialized tests to detect these changes are now part of the standard of care for advanced lung cancer and are performed on tumor tissue, as well as, in some cases, on blood samples. However, studies have shown that not all patients who would benefit from these tests actually receive them.

The goal of the CRISP study is to establish a Germany-wide research platform for patients with NSCLC and SCLC. Data will be collected on specific treatment measures, tests conducted before the start of treatment, and the impact on patients’ lives and mental well-being. The study aims to collect as much patient data as possible to improve our understanding of lung tumors. By collecting this data, researchers hope to assess how existing guidelines and recommendations for lung tumors are being implemented in practice and identify areas where improvements are still needed. In addition, tissue samples will be preserved and made available for future research. To this end, patients will be grouped within the study based on tumor type, disease stage, and treatment. No new therapies are being tested in this study; it is a registry study. Follow-up as part of the study will last for up to 3 years.

Women and men aged 18 and older who have been diagnosed with NSCLC or SCLC are eligible to participate in the study. Various disease stages and treatment regimens are accepted for participation in the study. Enrollment may occur at the time of diagnosis, up to a maximum of 4 weeks after the start of the first cancer treatment, or up to a maximum of 4 weeks after switching to the “best supportive care” (BSC) treatment approach. BSC does not involve cancer treatment but rather a form of care that treats only the symptoms caused by the cancer.